+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Geriatric Medicines Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4997429
  • Report
  • March 2020
  • Region: Global
  • 120 pages
  • Mordor Intelligence
1 of 4


  • Allergan Inc
  • AstraZeneca plc
  • AstraZeneca PLC
  • Endo Pharmaceuticals Inc
  • F. Hoffmann-La Roche AG
  • Merck & Co Inc
  • MORE
The geriatric medicines market studied was anticipated to grow with a CAGR of nearly 6.5% during the forecast period. The major factor attributing to the growth of the market is a steep rise in the elderly population across the geographical locations, mainly in developed and emerging economies. Also, rising prevalence of chronic disorders such as cancers, diabetes, and rheumatoid arthritis among the geriatrics attributes for the growth of the market. For instance, according to the United Nations data of World Population Prospects for the year 2019, number of people over the age 65 increases from 9% in 2019 to more than 16% of the total world’s population by 2050. Also, the number of persons aged 80 years or over is projected to triple, from 143 million in 2019 to 426 million in 2050. Thus, the rise in the volume of patient pool results in the higher demand for the market fueling the global market growth over the forecast period.

Key Market Trends

Analgesics in Therapeutics Segment is Expected to Hold the Largest Market Share in the Geriatric Medicines Market

The analgesics segment is expected to account for the largest revenue over the forecast period as it is the most common indication with high occurrence rate of pain related syndromes in the elder age. This dominance is due to occurrence of various reasons such as osteoporosis, lack of musculo-skeletal strength, vision impairment, and unintentional falls leading to unbearable pain in that age. Thus, owing to several distinct syndromes, the demand for proper analgesic therapy increases with rise in prescription sales for pain management is more and is anticipated to the growth of the segment. On the other hand, the anti-diabetic segment is expected to witness the fastest CAGR due to increasing global burden of diabetes in the elderly age group which results in other ailments resulting in higher demand for the segment driving the market revenue over the forecast period.

North America Dominates the Market and Expected to do Same in the Forecast Period.

North America is expected to dominate the overall geriatric medicines market throughout the forecast period. The dominance is due to growing prevalence of various chronic diseases like obesity and diabetes, presence of huge population of baby boomers during the forecast period in the United States necessitating the efficient treatment. For instance, according to the International Diabetes Federation in 2019, about 48 million adults in the North America are living with diabetes, among which more than half of the patients are over the age of 65 and are expected to continue in the future resulting in higher demand for the specific treatment for geriatric population driving the market in the region. Moreover, the rise in demand for geriatric care can be attributed to the increased side-effects due to several interactions among various medicines associated with the poly-pharmacy, especially those who are not residing in nursing homes, rise in government initiatives to enhance the awareness, a well-developed compensation scenario along with an increased availability of advanced healthcare infrastructure and huge investments by the key players in region are likely to fuel the market growth contributing to its outstanding market share in the global geriatric medicines market

Competitive Landscape

The geriatric medicines market is moderately competitive and consists of several major players. Few of the prominent players currently dominating the market are implementing various strategies like developing products specific to elderly patients minimizing the side effects while some others are focusing on the R&D activities, applying for Investigational New Drug (IND) application approvals with huge product pipelines to treat rare autoimmune disorders which are more prevalent in these patients to consolidate their market positions across the globe. For example, in September 2019, Akari Therapeutics Plc, a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases has received orphan drug designation for nomacopan from the U.S. Food and Drug Administration (FDA) which was successfully proven efficient in animals models of Guillain-Barre syndrome driving the market growth. Some of the companies which are currently dominating the market are Endo Pharmaceuticals Inc, Merck & Co Inc, AstraZeneca PLC, Pfizer Inc, and Allergan Inc

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • 3 months of analyst support.
Note: Product cover images may vary from those shown
2 of 4


  • Allergan Inc
  • AstraZeneca plc
  • AstraZeneca PLC
  • Endo Pharmaceuticals Inc
  • F. Hoffmann-La Roche AG
  • Merck & Co Inc
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Affordability along with Availability of Products Specific to these Population
4.2.2 Steep Rise in Growth of Elderly Population and Prevalence of Chronic Conditions
4.3 Market Restraints
4.3.1 Lack of Awareness and Proper Care Among the Elderly Patients
4.3.2 High Cost of Medicines and Treatment
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 Therapeutic Category
5.1.1 Analgesics
5.1.2 Antidiabetics
5.1.3 Antihypertensives
5.1.4 Antidepressants
5.1.5 Others
5.2 End-User
5.2.1 Hospital Pharmacies
5.2.2 Online Pharmacies
5.2.3 Retail Pharmacies
5.3 Geography
5.3.1 North America United states Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Endo Pharmaceuticals Inc
6.1.2 Merck & Co Inc
6.1.3 AstraZeneca PLC
6.1.4 Pfizer Inc
6.1.5 Allergan Inc
6.1.6 Bristol-Myers Squibb Company
6.1.7 Regeneron Pharmaceuticals Inc
6.1.8 AstraZeneca plc
6.1.9 F. Hoffmann-La Roche AG
6.1.10 Octapharma AG

Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • Endo Pharmaceuticals Inc
  • Merck & Co Inc
  • AstraZeneca PLC
  • Pfizer Inc
  • Allergan Inc
  • Bristol-Myers Squibb Company
  • Regeneron Pharmaceuticals Inc
  • AstraZeneca plc
  • F. Hoffmann-La Roche AG
  • Octapharma AG
Note: Product cover images may vary from those shown